Mektovi (binimetinib) — Medica
non-small cell lung cancer (NSCLC)
Initial criteria
- age ≥ 18 years
- recurrent, advanced, or metastatic NSCLC
- BRAF V600E mutation-positive disease
- used in combination with Braftovi (encorafenib)
Approval duration
1 year
non-small cell lung cancer (NSCLC)
1 year